H.B. Fuller rejected an unsolicited bid from Ancora Holdings and initiated a market check, while analysts suggest the stock is 27% undervalued due to ongoing margin optimization initiatives.
Ancora Holdings urges H.B. Fuller to pursue a full sale after rejecting a $1.2–1.4 billion offer for its adhesive segment, citing poor stock performance and debt.
HB Fuller Sr. VP Heather Campe filed a Form 4 on October 23rd, as reported by Investing.com.
H.B. Fuller shares are analyzed as undervalued via DCF model despite a five-year decline, following a board decision to reject an offer for a key business segment.
HB Fuller Company filed a Form 8K on October 22, 2026. The filing announcement provides limited details beyond the company name and submission date.
H.B. Fuller rejected a second unsolicited takeover bid from Ancora Holdings for its Building Adhesive Solutions business due to valuation disputes. The company subsequently announced a market review f
UBS reduced HB Fuller's price target to $55 from $69, reflecting a cautious outlook on the specialty adhesives and coatings firm's stock performance.
H.B. Fuller rejected activist investor Ancora's $1.2–1.4 billion offer for its Building Adhesive Solutions unit, deeming it modest. The company will conduct a market check of other segments by year-en
H.B. Fuller's board rejected Ancora's second unsolicited $1.2–1.4 billion offer for its Building Adhesive Solutions segment, deeming it insufficient. The company will conduct a market check on select
H.B. Fuller rejected Ancora Holdings Group's increased $1.2 billion to $1.4 billion offer for its Building Adhesive Solutions business, deeming it undervalued. Subsequently, the company initiated a ma
H.B. Fuller VP Muhammad Shahbaz Malik bought 479 shares after reporting adjusted EPS of $1.52, beating estimates despite revenue missing expectations. Analysts maintain a Moderate Buy rating with a pr
H.B. Fuller rejected Ancora's $1.2-1.4 billion offer for its building adhesives business, citing undervaluation. The company now plans to review and potentially separate noncore segments less integral
H.B. Fuller's board unanimously rejected Ancora's unsolicited $1.2–$1.4 billion takeover bid for its Building Adhesive Solutions division, deeming the offer undervalued.
H.B. Fuller rejected Ancora's $1.2–1.4 billion bid for its Building Adhesive Solutions business citing inadequate valuation. The company plans a market check for non-integral assets to fund debt reduc
HB Fuller Company director R. Jeffrey Bailly filed a Form 4 regulatory disclosure for insider transactions ending September 30.
HB Fuller Company reported a Form 4 filing for Sr. VP Heather Campe regarding activity on October 9th. The filing details were not included in the Investing.com article published on October 17, 2026.
Deutsche Bank reduced its price target for H.B. Fuller to $62.00 from $72.00 while maintaining a Buy rating. The company's stock trades at EUR 45.80 ahead of its next earnings report on January 13, 20
H.B. Fuller Executive VP and CFO John J. Corkrean purchased 254.31 phantom units at $49.56 per unit on October 9, 2026. Following the transaction, his reported phantom-unit balance increased to 36,405
An insider purchased an additional US$500,000 worth of H.B. Fuller Company stock, signaling positive investor confidence in its valuation. The transaction highlights continued market interest in the s
H.B. Fuller Director R. Bailly purchased $500k worth of shares at $50 each, marking the largest insider buy in a year. This move signals strong insider confidence above the current market price.
H.B. Fuller Company (FUL) shares closed at $49.56 with a new dividend of $0.245 announced for October 2026. Analysts forecast an average price target of $68.29 for the adhesives and chemical products
HB Fuller Company submitted a Form 4 filing to the SEC on October 10 regarding beneficial ownership changes. Specific transaction details were not disclosed in this brief announcement.
H.B. Fuller Director R. Jeffrey Bailly purchased $500,000 in shares near the 52-week low. The company reported mixed Q3 2026 earnings with EPS beating expectations but revenue falling short.
H.B. Fuller has priced $850 million of senior unsecured notes due in 2034 at a 7.625% interest rate through a private offering to secure long-term debt financing.
H.B. Fuller priced $850 million in senior unsecured notes due 2034. Proceeds will fund the acquisition of Advanced Medical Solutions Group plc, repay debt, and support general corporate purposes.
An H.B. Fuller insider purchased $500,000 worth of shares per a recent SEC filing, while the board continues to reject acquisition attempts by Ancora Holdings Group for its Building Adhesive Solutions
H.B. Fuller director R. Jeffrey Bailly bought 10,000 shares at $50 each through a trust on October 7, 2026, according to SEC filings. The move signals positive insider sentiment for the adhesive and c
H.B. Fuller issued $950 million in senior unsecured notes to finance the acquisition of Advanced Medical Solutions Group plc, with provisions for redemption if the deal fails to close by the outside d
Analysts set H.B. Fuller's consensus target at $64.62 with a 'Moderate Buy' rating after an EPS beat and 5.2% revenue rise. Insider buying signals confidence in the chemical firm's outlook.
HB Fuller Company director R. Jeffrey Bailly received 1,300 restricted stock units on September 30, 2026, converting to common stock with an expiration date of September 30, 2029.
H. B. Fuller Company announced a quarterly dividend of $0.245 per share, marking its 57th consecutive year of dividend increases. The specialty chemicals firm also reported strong quarterly EPS of $1.
H.B. Fuller board member Srilata Zaheer bought 2,040 shares worth over $100,000, indicating confidence in the adhesive manufacturer despite revenue challenges. The insider purchase reflects an attract
H.B. Fuller director Michael Happe purchased 2,000 shares, increasing ownership by 149%, while the company reported quarterly earnings per share of $1.52 despite revenue falling short of expectations.
H.B. Fuller director Srilata Zaheer purchased 2,000 shares, increasing ownership by 148%, while the company reported better-than-expected quarterly EPS of $1.52 and 5.2% revenue growth.
H.B. Fuller director Thomas Handley purchased $98,820 worth of shares while the stock traded near its 52-week low. Despite better-than-expected adjusted earnings, revenue misses led Baird to lower its
H.B. Fuller director Charles T. Lauber purchased 2,005 shares totaling $99,984 as the stock trades near its 52-week low. His direct holdings now exceed 16,000 shares plus convertible units.
H.B. Fuller appointed R. Jeffrey Bailly to its board to enhance medical technology expertise, aligning with a focus on higher-margin healthcare exposure while facing activist investor pressure for a s
H.B. Fuller appointed R. Jeffrey Bailly to its Board of Directors to leverage his manufacturing and medical technology expertise. The appointment supports the company's strategic shift toward higher-m
H.B. Fuller reported Q3 2026 revenue of $938 million and adjusted EBITDA of $187 million. The company raised its full-year EBITDA outlook to $655–$670 million and noted an anticipated AMS acquisition.
H. B. Fuller reported strong Q3 fiscal 2026 results with revenue up 5.2% and EBITDA up 9%, driven by pricing strategies despite high raw material costs. The company also plans to acquire Advanced Medi
H.B. Fuller shares declined following its fiscal third-quarter earnings report, where the chemical company missed net revenue expectations despite beating adjusted profit estimates amid guidance conce
H. B. Fuller issued FY 2026 EPS guidance of $4.70-$4.85, below analyst consensus, and declared a $0.245 quarterly dividend. Shares traded down following the announcement.
H.B. Fuller is scheduled to report Q3 2026 earnings on September 24, with analysts forecasting $1.46 EPS and $945.5 million revenue. Investors will focus on raw material costs and margin improvements
H.B. Fuller has launched the Kōfinity™ portfolio, utilizing its 4SG technology to create fusion bonded spacers for insulating glass solutions. This innovation aims to eliminate window seal failures wh
H.B. Fuller has launched Kōfinity, a new insulating glass product line featuring 4SG reactive thermoplastic spacer technology. The innovation targets window seal failures such as fogging by employing
H.B. Fuller shares dropped to a new 52-week low of $48.60 despite reporting better-than-expected quarterly earnings. The decline coincided with significant insider selling by VP Nathan Weaver, contras
H.B. Fuller is set to report Q3 2026 earnings on September 23rd, with analysts forecasting $1.47 EPS and $948.2 million revenue. The stock maintains a Buy consensus with a price target of $67.86 follo
H.B. Fuller Company will release its Q3 2026 financial results after market close on September 23, 2026. An investor conference call and webcast will follow on September 24 to discuss the findings.
H.B. Fuller received a consensus 'Buy' rating from analysts after reporting quarterly earnings of $1.41 EPS against estimates, with revenue growing 5.8% year-over-year.
H.B. Fuller is expanding Gel-Tac™ microsphere adhesive production at its Italian Pianezze facility to enhance supply responsiveness and reduce carbon footprints. Additionally, the company is developin
ChemBrief